Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Eidos Therapeutics (EIDX) stocks in Canada

Learn how to easily invest in Eidos Therapeutics stocks.

Eidos Therapeutics is a biotechnology business based in the US. Eidos Therapeutics stocks (EIDX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Eidos Therapeutics employs 70 staff and has a trailing 12-month revenue of around $127,000.

How to buy stocks in Eidos Therapeutics

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EIDX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Eidos Therapeutics stock price (NASDAQ:EIDX)

Use our graph to track the performance of EIDX stocks over time.

Eidos Therapeutics shares at a glance

Information last updated 2021-03-21.
52-week range$0.00 - $0.00
50-day moving average $124.31
200-day moving average $77.38
Wall St. target price$53.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.27

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Eidos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Eidos Therapeutics financials

Revenue TTM $127,000
Gross profit TTM $24.2 million
Return on assets TTM -35.95%
Return on equity TTM -70.31%
Profit margin 0%
Book value $3.18
Market capitalisation $4.8 billion

TTM: trailing 12 months

Eidos Therapeutics share dividends

We're not expecting Eidos Therapeutics to pay a dividend over the next 12 months.

Eidos Therapeutics share price volatility

Over the last 12 months, Eidos Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eidos Therapeutics's is -0.1678. This would suggest that Eidos Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Eidos Therapeutics has bucked the trend.

Eidos Therapeutics overview

Eidos Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc. .

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site